Yahoo Finance

Operations: New Found Gold Corp. does not report any revenue segments as it is primarily engaged in the exploration of mineral properties.

Market Cap: CA$282.86M

New Found Gold Corp., with a market cap of CA$282.86 million, is pre-revenue and focused on mineral exploration in Newfoundland and Labrador. The company recently announced an initial Mineral Resource Estimate for its Queensway Gold Project, highlighting significant high-grade gold zones like Keats and Iceberg. Despite being debt-free with short-term assets exceeding liabilities, New Found faces financial challenges with less than a year of cash runway. Recent management changes include the appointment of Keith Boyle as CEO, bringing extensive mining experience to support ongoing exploration efforts aimed at expanding resource potential amidst going concern doubts from auditors.

• Dive into the specifics of New Found Gold here with our thorough balance sheet health report.

• Gain insights into New Found Gold's outlook and expected performance with our report on the company's earnings estimates.

Theralase Technologies

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research, development, and commercialization of light activated photodynamic compounds for treating cancers, bacteria, and viruses across Canada, the United States, and internationally with a market cap of CA$42.30 million.

Operations: The company generates CA$1.03 million in revenue from its device segment.

Market Cap: CA$42.3M

Theralase Technologies Inc., with a market cap of CA$42.30 million, is pre-revenue, focusing on innovative cancer treatments and viral therapies. Recent clinical developments include promising results from its lead compound RuvidarTM in treating non-muscle invasive bladder cancer and Herpes Simplex Virus Type 1. Despite these advances, the company faces financial hurdles with an auditor expressing going concern doubts and limited cash runway, although recent capital raising efforts provide some relief. The management team has substantial experience, yet the company's negative return on equity reflects ongoing profitability challenges as it continues to invest in research and development initiatives.

• Get an in-depth perspective on Theralase Technologies' performance by reading our balance sheet health report here.

• Assess Theralase Technologies' future earnings estimates with our detailed growth reports.

Where To Now?

• Reveal the 934 hidden gems among our TSX Penny Stocks screener with a single click here.

• Seeking Other Investments? The latest GPUs need a type of rare earth metal called Terbium and there are only 20 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TSXV:GPH TSXV:NFG and TSXV:TLT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com